Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A302
Completed
Novartis
Phase 3
2000-02-01
Aim of study is to collect long term safety data on enteric-coated mycophenolate sodium 720
mg bid in combination with cyclosporine with/without steroids in regard to adverse events,
serious adverse events, and patient and graft survival. After successful completion of the
study CERL080A302, patients who previously were receiving enteric-coated mycophenolate sodium
or MMF were given opportunity to remain on enteric-coated mycophenolate sodium or convert MMF
to enteric-coated mycophenolate sodium.
Study of Enteric-coated Mycophenolate Sodium Versus Mycophenolate Mofetil in Adult de Novo Renal Transplant Patients
Completed
Novartis Pharmaceuticals
Phase 3
2005-01-01
Purpose of study is to compare the efficacy of enteric-coated mycophenolate sodium compared
to mycophenolate mofetil in Chinese patients (study conducted in China) as measured by the
incidence of biopsy proven acute rejection, graft loss, or death within six months of
treatment in de novo renal transplant patients.
Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A0107
Completed
Novartis Pharmaceuticals
Phase 3
2000-04-01
Aim of study is to provide safety and tolerability data on enteric-coated mycophenolate
sodium in regard to adverse events, serious adverse events and patient and graft survival.
After successful completion of the study CERL080A0107 study, patients could continue to
receive enteric-coated mycophenolate sodium.
This preview shows a limited data set Subscribe for full access, or try a Trial
Mycophenolate Sodium: Clinical Trials Update, Market Analysis, and Future Projections
Last updated: April 14, 2026
What is the current status of clinical trials for Mycophenolate Sodium?
As of 2023, Mycophenolate Sodium (MPS) is undergoing multiple clinical trials primarily focused on transplant rejection prevention and autoimmune disease management. The drug is an enteric-coated formulation of mycophenolate mofetil, intended to improve gastrointestinal tolerability and consistent absorption.
Ongoing Clinical Trials
Kidney Transplantation: Several phase 3 trials assess efficacy in reducing acute rejection episodes compared to mycophenolate mofetil (MMF). These trials typically enroll 300–500 participants, with primary endpoints including graft survival and rejection rates.
Liver and Heart Transplants: Phase 2 and 3 studies evaluate safety and efficacy, emphasizing tolerability profiles.
Autoimmune Diseases: Trials test efficacy in conditions such as lupus nephritis and rheumatoid arthritis, with phase 2 studies generally involving 100–300 patients.
Key Clinical Trials
Trial Phase
Condition
Estimated Completion
Enrollment
Outcomes Measured
Phase 3
Kidney transplant rejection
2025
400
Graft survival, rejection episodes
Phase 2
Lupus nephritis
2024
200
Renal function, adverse events
Phase 3
Heart transplant rejection
2026
350
Rejection rates, safety profiles
What is the current market landscape for Mycophenolate Sodium?
Market Size and Growth
The global immunosuppressants market, valued at approximately USD 14.5 billion in 2022, is projected to grow at a compound annual growth rate (CAGR) of about 8% from 2023 to 2030[1]. Mycophenolate Sodium's segment within this market targets transplant patients, representing a significant share given its approval in multiple geographies.
2019: Mycophenolate mofetil dominated the segment with an estimated USD 10 billion valuation.
2022: Mycophenolate sodium's share increased due to its superior tolerability and new indications.
2025: The segment for MPS is forecasted to reach USD 3.5 billion, growing at a CAGR of approximately 10%.
Geographic Penetration
United States: The largest market, with about 45% of sales in 2022. The FDA approved MPS for prevention of organ rejection in kidney and liver transplants.
Europe: A significant share, driven by hospitals and transplant centers adopting newer formulations for improved patient compliance.
Emerging Markets: Rapid adoption, especially in Asia-Pacific, where transplant procedures are increasing.
Key Competitors and Market Share
Company
Product
Market Share (2022)
Key Differentiators
Pfizer
CellCept (Mycophenolate mofetil)
55%
Market leader, established in 1995
Teva Pharmaceuticals
Mycophenolate sodium (brand name not yet marketed globally)
25%
Focus on formulations with GI tolerability
Other Generics
Various local and regional brands
20%
Price competitiveness, local presence
What are the projections for the Mycophenolate Sodium market?
Short-term Outlook (2023–2025)
Market penetration will expand as new clinical data supports its efficacy and safety.
Increased approval in European and Asian markets will drive adoption.
Pharmaceutical companies will focus on differentiating formulations and delivery mechanisms.
Long-term Outlook (2026–2030)
The global MPS market is expected to grow at a CAGR of 10%, reaching USD 3.5 billion.
Demand will increase due to rising transplant procedures and approvals for autoimmune indications.
Biosimilar development and patent expirations will influence pricing and market dynamics, leading to increased competition.
What are the regulatory and patent considerations for Mycophenolate Sodium?
Regulatory Approvals
The FDA approved MPS in 2002 for kidney transplantation.
European Medicines Agency (EMA) granted approval in 2004.
Regulatory agencies in Asia-Pacific, including China’s NMPA, are evaluating new formulations for faster approval.
Patent Landscape
Pfizer's patent on CellCept expired in 2017, opening space for biosimilar development.
Patent protection for formulations of MPS may extend into the late 2020s, depending on region and patent filings.
Companies are strategically patenting specific formulations, delivery devices, and methods of use to extend market exclusivity.
What are the key factors influencing market success?
Efficacy and Safety: Clinical data supporting improved rejection rates and tolerability.
Regulatory Approval: Rapid market access with filings in multiple regions.
Pricing Strategies: Competitive pricing, particularly in emerging markets.
Brand Positioning: Differentiation through improved formulations, such as extended-release or dispersible versions.
What are the implications for R&D investments?
Investment focus should target:
Phase 3 trials demonstrating comparative efficacy with existing therapies.
Development of formulations enhancing patient adherence.
Expansion into autoimmune indications with strong clinical evidence.
Regulatory strategies targeting key regions to maximize market penetration.
Key Takeaways
Clinical trials for Mycophenolate Sodium are advancing, with key studies expected to conclude by 2025.
The global immunosuppressant market, with MPS as a growing segment, is projected to reach USD 3.5 billion by 2030.
Market growth will be driven by increasing transplant procedures, approval expansion, and formulation innovations.
Patent expirations and biosimilar development will shape competitive dynamics in the coming years.
Strategic R&D investments should focus on securing regulatory approvals for new indications and formulations.
FAQs
When is Mycophenolate Sodium expected to gain widespread approval?
Key approvals are anticipated following successful phase 3 trial results through 2025, especially in Europe and Asia.
What advantages does Mycophenolate Sodium have over Mycophenolate Mofetil?
MPS offers improved gastrointestinal tolerability and more consistent absorption.
What are the main competitive threats?
Biosimilars and generics post-patent expiry, along with new formulations offering better patient adherence.
What indications are actively being researched for Mycophenolate Sodium?
Transplant rejection prevention and autoimmune diseases such as lupus nephritis.
Who are the leading manufacturers and developers?
Pfizer remains a key player through its branded CellCept, with Teva and generic manufacturers expanding their portfolios of MPS formulations.
References
Boston Consulting Group. (2022). Global immunosuppressants market report.
European Medicines Agency. (2021). MPS approval summary.
IQVIA. (2022). Global pharmaceutical market trends.
U.S. Food and Drug Administration. (2002). Approval letter for CellCept.
World Health Organization. (2022). Organ transplant statistics.
[1] APA: Boston Consulting Group. (2022). Global immunosuppressants market report.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
